Literature DB >> 15628756

[Chemotherapy for hepatocellular carcinoma].

Takuji Okusaka1, Hideki Ueno, Masafumi Ikeda.   

Abstract

Patients with hepatocellular carcinoma (HCC) frequently show early recurrence even after hepatic resection and local ablation therapy. Moreover, many patients exhibit multiple HCC with or without distant metastasis at the time of initial diagnosis. Accordingly, to improve the overall survival of patients with HCC, effective systemic treatment, including chemotherapy, is needed. No agent has reproducibly documented a high response rate, and few chemotherapeutic regimens show meaningful impact on patient survival. Numerous clinical trials have been conducted to establish effective treatment for patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15628756

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.

Authors:  Wei Geng; Kevin T P Ng; Chris K W Sun; Wing Lung Yau; Xiao Bing Liu; Qiao Cheng; Ronnie T P Poon; Chung Mau Lo; Kwan Man; Sheung Tat Fan
Journal:  PLoS One       Date:  2011-11-09       Impact factor: 3.240

2.  Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.

Authors:  Hiroki Nishikawa; Yukio Osaki; Ryuichi Kita; Toru Kimura
Journal:  Cancers (Basel)       Date:  2012-02-21       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.